Kite Pharma partners with Japan's Daiichi for cancer therapy
(Reuters) - Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.
Authors: Botti G, Cantile M PMID: 30303033 [PubMed - as supplied by publisher]
The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy . More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches . Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly  and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial .
Paolo Ciana Oncolytic viruses (OV) are engineered to infect, replicate in and kill cancer cells. Currently, the OV therapeutic approach is mainly restricted to neoplasia amenable to direct local administration of viral particles, while the possibility of a systemic delivery of cancer-tropic viruses would extend the OV application to the treatment of metastatic neoplasia. Herein, we applied in vivo/ex vivo imaging to demonstrate that cancer tropism is achieved when OV are encapsulated inside extracellular vesicles (EV) administered intravenously (i.v.), but not when injected intraperitoneally (i.p.). Moreover, we show t...
Publication date: Available online 12 October 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Arseniy E. Yuzhalin, Su Yin Lim, Anton G. Kutikhin, Alex N. Gordon-WeeksAbstractThe main cause of cancer-related mortality, metastasis, is a complex, multi-step process. The extracellular matrix (ECM) component of solid tumors has been implicated in metastatic progression; however, the ECM exists as a complex macromolecular substrate and it is unclear how its molecular composition promotes cancer progression. ECM homeostasis is regulated by various secreted proteins including cross-linkers (e.g., lysy...
Authors: Schanz M, Schricker S, Pfister F, Alscher MD, Kimmel M Abstract Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects. Direct toxicit...
Publication date: Available online 11 October 2018Source: The Annals of Thoracic SurgeryAuthor(s): Hideki Ujiie, Lili Ding, Rong Fan, Tatsuya Kato, Daiyoon Lee, Kosuke Fujino, Tomonari Kinoshita, Chang Young Lee, Thomas K. Waddell, Shaf Keshavjee, Brian C. Wilson, Gang Zheng, Juan Chen, Kazuhiro YasufukuAbstractBackgroundWe have developed ultra-small porphyrin-lipoprotein nanoparticles (
In conclusion, the synthesized DOX@nanocomposite can be applied in theranostic applications and anticancer drug delivery owing to admissible properties. PMID: 30307331 [PubMed - as supplied by publisher]
(University of California - San Diego) Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune response.
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.8b14517